Amgen leverages biology and technology to fight tough diseases and improve lives. For over 40 years, we’ve pioneered biotechnology, creating innovative medicines for millions. Using genetic insights and cutting-edge research, Amgen continues to push boundaries, delivering breakthroughs that make life easier, fuller, and longer.
Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases. Chiesi Group strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. The goal of the Global Rare Diseases unit is to ensure equal access so as many people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system. For more information visit www.chiesirarediseases.com.
×
DOMPÉ
Dompé farmaceutici S.p.A. is a privately held, global biopharmaceutical company on a mission to bring the full potential of nerve growth factor (NGF) to patients. As the first company to unlock the therapeutic potential of NGF, Dompé developed the first FDA-approved NGF treatment. Today, our clinical pipeline reflects our commitment to redefining treatments across ophthalmic, neurological and pain-related conditions. Building on 130 years of independence, we are embracing the challenge to transform our science and ourselves by delivering first-in-class, disease-modifying therapies through NGF and other breakthrough molecules to help people improve their sight, support neurological recovery and manage pain effectively. Today, Dompé employs more than 950 employees worldwide and maintains a US commercial operations hub in the San Francisco Bay Area. Learn more at https://www.dompe.com/us/.
×
OMIKRON
Omikron Italia is a Pharmaceutical Company established in 2005 and specialized in the treatment of major neurodegenerative ophthalmic diseases with the aim of improving patients’ quality of life. Since January 2021, it has been part of the Opocrin SpA Industrial Group, a leading company in the production of active pharmaceutical principles. Omikron Italia is an Evidence Based Company and invests 15% of its turnover in Research and Development every year by conducting the most important existing trials on Neuroprotection in Glaucoma. The company holds the International Patent for Citicoline eye drops and a Patent for Citicoline and Nicotinamide oral solution. Furthermore, it has developed and registered with the Italian Ministry of Health and in 3 European Countries the first oral Neuroprotector (FSMP category) indicated for Glaucoma, based on Citicoline oral solution. To find out more, visit https://www.omikronitalia.it/en/.
